AVNSHealthcare · Medical DevicesConsensus tells you what everyone already believes. The model scores Avanos Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
We don’t hold a current model rank for this company.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AVNS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 May 2024 | JMP Securities | Reiterates | Market Perform | — |
| 25 July 2023 | Keybanc | Downgrade | Sector Weight | — |
| 21 June 2023 | Stifel | Reiterates | Hold | — |
| 22 May 2023 | CL King | Initiates | Buy | — |
| 4 May 2023 | Morgan Stanley | Maintains | Underweight | — |
| 22 Feb 2023 | Morgan Stanley | Maintains | Underweight | — |
| 6 Jan 2023 | Morgan Stanley | Maintains | Underweight | — |
| 3 Nov 2022 | Keybanc | Maintains | Overweight | — |
| 11 Oct 2022 | Morgan Stanley | Maintains | Underweight | — |
| 10 Aug 2022 | Keybanc | Maintains | Overweight | — |
| 18 July 2022 | Stifel | Maintains | Hold | — |
| 15 July 2022 | Morgan Stanley | Maintains | Underweight | — |
| 5 May 2022 | Morgan Stanley | Maintains | Underweight | — |
| 24 Feb 2022 | Keybanc | Maintains | Overweight | — |
| 7 Jan 2022 | Morgan Stanley | Maintains | Underweight | — |
| 4 Aug 2021 | Keybanc | Maintains | Overweight | — |
| 4 Aug 2021 | Morgan Stanley | Maintains | Underweight | — |
| 4 Aug 2021 | Stephens & Co. | Downgrade | Equal-Weight | — |
| 8 Jan 2021 | Keybanc | Maintains | Overweight | $47 → $55 |
| 8 Jan 2021 | KeyBanc | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVNS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 July 2026, Avanos Medical, Inc. returned +110.4% against +17.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 23% of US stocks
Cheaper than 58% of US stocks
Cheaper than 57% of US stocks
Cheaper than 14% of US stocks
Higher than 49% of US stocks
Higher than 19% of US stocks
Higher than 64% of US stocks
Higher than 56% of US stocks
Higher than 20% of US stocks
Higher than 36% of US stocks
Higher than 49% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Avanos Medical, Inc. has a market value of $1.2B and an enterprise value of $1.2B.
Revenue in the twelve months to 31 Mar 2026: $715.9M. The latest quarter grew 8.8% year on year.
Net income over the same four quarters: −$74.4M, a −10.4% net margin.
Diluted earnings per share, trailing twelve months: $−1.61.
Free cash flow in the twelve months to 31 Mar 2026: $7.5M.
Avanos Medical, Inc. spent $2.4M on share buybacks in the twelve months to 31 Mar 2026.
Trailing P/E: 34.4×; forward P/E: 20.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Avanos Medical, Inc. employs 2,287 people — $313K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| AVNSAvanos Medical, Inc. | $1.2B | — |
| LLYEli Lilly & Co.* | $1.2T | 91 |
| JNJJohnson & Johnson* | $650.8B | 92 |
| ABBVAbbVie, Inc.* | $468.1B | 96 |
| MRKMerck & Co., Inc.* | $378.6B | 83 |
| UNHUnitedHealth Group, Inc.* | $353.4B | 75 |
| AMGNAmgen, Inc.* | $236.8B | 92 |
* Nearest Healthcare names by size — few medical devices companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Avanos Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Sterlington advised the Avanos Medical management team on a $1.27 billion acquisition, according to a Business Wire announcement.
Why it matters — AVNS watchers would care because the $1.27 billion acquisition is a major corporate transaction involving the company's management team.
Of the 1 analysts covering Avanos Medical, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. None of this is personal advice — it does not consider your circumstances.
No analyst covering Avanos Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVNS are extrapolating price history, which says nothing about the business.
Avanos Medical, Inc. returned +110.4% over the 12 months to 24 July 2026, with dividends reinvested. Past performance does not indicate future returns.
Avanos Medical Inc. is a healthcare company specializing in the development and production of medical devices designed to improve patient outcomes and reduce procedural costs.
The most recent item we track (Business Wire, 29 July 2026): "Sterlington Advises Avanos Medical Management Team on $1.27 Billion Acquisition". Sterlington advised the Avanos Medical management team on a $1.27 billion acquisition, according to a Business Wire announcement.
Avanos Medical Inc. is a healthcare company specializing in the development and production of medical devices designed to improve patient outcomes and reduce procedural costs. Primarily focusing on chronic care and pain management solutions, Avanos Medical offers a diverse range of products, including enteral feeding systems, respiratory therapy equipment, and advanced pain management technologies. The company's products are utilized in various healthcare settings such as hospitals, home care environments, and outpatient facilities. With its commitment to innovative healthcare solutions, Avanos Medical plays a crucial role in enhancing patient care quality and operational efficiency in the medical sector. By continually evolving its product offerings, Avanos seeks to address the growing demands and challenges faced by healthcare providers worldwide.
CEO Mr. David C. Pacitti M.B.A. · 2,287 employees · United States · https://avanos.com
